knowledge -WSS

knowledge

author：leisure time 2025-09-28 19:24:58 - browse：12812

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Change Healthcare payments predicted restored March 15

WSS

Readout LOUD podcast: Live from the 2023 STAT Summit

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Summit: Ending the crisis of Black deaths in the U.S.

FDA clears Verve to begin U.S. study of gene

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

entertainment

knowledge

explore

The high cost of giving birth even with insurance

Sen. Paul opposes bill to ban Chinese biotechs

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

CDC marks new Covid

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: The economic case for universal basic health care

What does generative AI mean for health care? We asked experts

Health tech investors get more selective as pandemic boom fades

hotspot

UnitedHealth quietly bought dozens of outpatient centers

ADCs take center stage as promising cancer treatments

The problem with charging patients to message their doctors

Health tech investors get more selective as pandemic boom fades

How to bring more disabled researchers into academia

The drug industry has found itself all alone in Washington

explore

knowledge

leisure time

hotspot